Microcap Losers: Alpha Pro Tech (NYSEMKT:APT), Neuralstem(NYSEMKT:CUR), Hudson Technologies Inc. (NASDAQ:HDSN), Protalix BioTherapeutics(NYSEMKT:PLX), MediciNova Inc. (NASDAQ:MNOV)


Alpha Pro Tech Ltd (NYSEMKT:APT) VP Charles D. Montgomery unloaded 43,570 shares of the company’s stock in a transaction that occurred on Tuesday, September 23rd. The shares were sold at an average price of $2.90, for a total transaction of $126,353.00. Following the completion of the sale, the vice president now directly owns 145,920 shares in the company, valued at approximately $423,168. Alpha Pro Tech Ltd. (NYSEMKT:APT) in last trading activity moved down -20.18% to close at $4.43. Company weekly performance is -55.92% while its quarterly performance stands at 111.96%. Alpha Pro Tech Ltd. (NYSEMKT:APT) is -58.71% away from its 52 week high.

Neuralstem Inc. (NYSEMKT:CUR) on 11 October announced that the first patient was treated last week in the phase I trial testing NSI-566 human neural stem cells in the treatment of chronic spinal cord injury (cSCI) at the UC San Diego School of Medicine. The patient has been discharged from the hospital. The NSI-566/cSCI phase I trial will treat four patients who have thoracic spinal cord injuries (T2-T12) with stem cell transplants directly into the region of the injury, between one and two years post-injury. On last trading day Neuralstem, Inc. (NYSEMKT:CUR) moved down -12.79% to close at $2.66. Its volatility for the week is 16.24% while volatility for the month is 8.67%. CUR’s EPS growth for past 5 years was 6.10%. Neuralstem, Inc. (NYSEMKT:CUR) monthly performance is -19.88%.

Hudson Technologies, Inc. (NASDAQ:HDSN), announced that on October 16, 2014 the Environmental Protection Agency (EPA) Administrator Gina McCarthy signed the final rule pertaining to allowances for virgin production of HCFCs, primarily R-22, for 2015 through 2019. The final rule, which was the lowest proposed approach, provides for virgin R-22 allowances of approximately 22 million pounds in 2015, 18 million pounds in 2016, 13 million pounds in 2017, 9 million pounds in 2018 and 4 million pounds in 2019, with a final ban on all production effective January 1, 2020.On last trading day Hudson Technologies Inc. (NASDAQ:HDSN) moved down -5.69% to close at $3.81. Its volatility for the week is 13.31% while volatility for the month is 7.32%. HDSN’s sales growth for past 5 years was 12.00% and its EPS growth for past 5 years was -22.20%. Hudson Technologies Inc. (NASDAQ:HDSN) monthly performance is 20.57%.

Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) on Sept. 29 announced that its Board of Directors has appointed Mr. Moshe Manor as its new President and Chief Executive Officer. Mr. Manor will assume office on Nov. 2, 2014, when Dr. Aviezer will retire. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) has 21.63% insider ownership while its institutional ownership stands at 19.60%. In last trading activity company’s stock closed at $2.44.

MediciNova, Inc. (NASDAQ:MNOV) a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), on 8 October announced that it has received feedback from FDA’s Division of Gastroenterology and Inborn Errors Products regarding the study protocol and drug substance information for a Phase 2 clinical trial of MN-001 (tipelukast) in nonalcoholic steatohepatitis (NASH). Accordingly, MediciNova will incorporate FDA’s feedback into the study protocol and IND application and will submit the IND to FDA as soon as possible in order to conduct a Phase 2 clinical trial of MN-001 (tipelukast) in NASH. On Monday shares of MediciNova Inc. (NASDAQ:MNOV) closed at $3.61. Company’s EPS growth for next 5 years is recorded as 20.00%.


Leave a Reply

Your email address will not be published. Required fields are marked *